nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluoxymesterone—Mometasone—systemic scleroderma	0.462	1	CrCtD
Fluoxymesterone—NR3C1—Mometasone—systemic scleroderma	0.126	0.759	CbGbCtD
Fluoxymesterone—NR3C1—Prednisone—systemic scleroderma	0.0401	0.241	CbGbCtD
Fluoxymesterone—Testolactone—Mometasone—systemic scleroderma	0.0157	0.0487	CrCrCtD
Fluoxymesterone—Amcinonide—Mometasone—systemic scleroderma	0.0145	0.0448	CrCrCtD
Fluoxymesterone—Clobetasol propionate—Mometasone—systemic scleroderma	0.0141	0.0436	CrCrCtD
Fluoxymesterone—Fludrocortisone—Mometasone—systemic scleroderma	0.0141	0.0436	CrCrCtD
Fluoxymesterone—Desoximetasone—Mometasone—systemic scleroderma	0.0134	0.0415	CrCrCtD
Fluoxymesterone—Loteprednol—Mometasone—systemic scleroderma	0.0131	0.0405	CrCrCtD
Fluoxymesterone—Fluorometholone—Mometasone—systemic scleroderma	0.0131	0.0405	CrCrCtD
Fluoxymesterone—Triamcinolone—Mometasone—systemic scleroderma	0.0131	0.0405	CrCrCtD
Fluoxymesterone—Fluprednidene Acetate—Mometasone—systemic scleroderma	0.0131	0.0405	CrCrCtD
Fluoxymesterone—Betamethasone—Mometasone—systemic scleroderma	0.0128	0.0396	CrCrCtD
Fluoxymesterone—Dexamethasone—Mometasone—systemic scleroderma	0.0128	0.0396	CrCrCtD
Fluoxymesterone—Potassium Canrenoate—Prednisone—systemic scleroderma	0.0124	0.0385	CrCrCtD
Fluoxymesterone—Prednisolone—Mometasone—systemic scleroderma	0.012	0.0371	CrCrCtD
Fluoxymesterone—Hydrocortisone—Mometasone—systemic scleroderma	0.0115	0.0356	CrCrCtD
Fluoxymesterone—Danazol—Prednisone—systemic scleroderma	0.0105	0.0325	CrCrCtD
Fluoxymesterone—Hydrocortamate—Prednisone—systemic scleroderma	0.00913	0.0282	CrCrCtD
Fluoxymesterone—Cortisone acetate—Prednisone—systemic scleroderma	0.00884	0.0274	CrCrCtD
Fluoxymesterone—Testolactone—Prednisone—systemic scleroderma	0.00858	0.0266	CrCrCtD
Fluoxymesterone—Amcinonide—Prednisone—systemic scleroderma	0.00789	0.0244	CrCrCtD
Fluoxymesterone—Clobetasol propionate—Prednisone—systemic scleroderma	0.00768	0.0238	CrCrCtD
Fluoxymesterone—Fludrocortisone—Prednisone—systemic scleroderma	0.00768	0.0238	CrCrCtD
Fluoxymesterone—Methyltestosterone—Prednisone—systemic scleroderma	0.00749	0.0232	CrCrCtD
Fluoxymesterone—Desoximetasone—Prednisone—systemic scleroderma	0.00731	0.0226	CrCrCtD
Fluoxymesterone—Triamcinolone—Prednisone—systemic scleroderma	0.00714	0.0221	CrCrCtD
Fluoxymesterone—Loteprednol—Prednisone—systemic scleroderma	0.00714	0.0221	CrCrCtD
Fluoxymesterone—Fluprednidene Acetate—Prednisone—systemic scleroderma	0.00714	0.0221	CrCrCtD
Fluoxymesterone—Mometasone—Prednisone—systemic scleroderma	0.00714	0.0221	CrCrCtD
Fluoxymesterone—Fluorometholone—Prednisone—systemic scleroderma	0.00714	0.0221	CrCrCtD
Fluoxymesterone—Dexamethasone—Prednisone—systemic scleroderma	0.00697	0.0216	CrCrCtD
Fluoxymesterone—Betamethasone—Prednisone—systemic scleroderma	0.00697	0.0216	CrCrCtD
Fluoxymesterone—Prednisolone—Prednisone—systemic scleroderma	0.00653	0.0202	CrCrCtD
Fluoxymesterone—Hydrocortisone—Prednisone—systemic scleroderma	0.00627	0.0194	CrCrCtD
Fluoxymesterone—Peliosis hepatis—Azathioprine—systemic scleroderma	0.00431	0.126	CcSEcCtD
Fluoxymesterone—Polycythaemia—Mycophenolic acid—systemic scleroderma	0.00223	0.0654	CcSEcCtD
Fluoxymesterone—Polycythaemia—Mycophenolate mofetil—systemic scleroderma	0.00176	0.0516	CcSEcCtD
Fluoxymesterone—PRLR—Signaling events mediated by PTP1B—CSF1—systemic scleroderma	0.00148	0.105	CbGpPWpGaD
Fluoxymesterone—ESR1—FOXM1 transcription factor network—CENPB—systemic scleroderma	0.00137	0.0971	CbGpPWpGaD
Fluoxymesterone—PRLR—Signaling events mediated by PTP1B—CSK—systemic scleroderma	0.00131	0.0926	CbGpPWpGaD
Fluoxymesterone—Polycythaemia—Prednisone—systemic scleroderma	0.00119	0.035	CcSEcCtD
Fluoxymesterone—PRLR—Signaling events mediated by PTP1B—BLK—systemic scleroderma	0.00114	0.0806	CbGpPWpGaD
Fluoxymesterone—Oligospermia—Methotrexate—systemic scleroderma	0.00104	0.0305	CcSEcCtD
Fluoxymesterone—Hirsutism—Mycophenolic acid—systemic scleroderma	0.000837	0.0246	CcSEcCtD
Fluoxymesterone—Azoospermia—Methotrexate—systemic scleroderma	0.000808	0.0237	CcSEcCtD
Fluoxymesterone—Jaundice cholestatic—Captopril—systemic scleroderma	0.000704	0.0207	CcSEcCtD
Fluoxymesterone—Hirsutism—Mycophenolate mofetil—systemic scleroderma	0.000661	0.0194	CcSEcCtD
Fluoxymesterone—Coagulopathy—Mycophenolic acid—systemic scleroderma	0.000625	0.0183	CcSEcCtD
Fluoxymesterone—Jaundice cholestatic—Azathioprine—systemic scleroderma	0.000615	0.018	CcSEcCtD
Fluoxymesterone—Anaphylactoid reaction—Pentoxifylline—systemic scleroderma	0.000612	0.018	CcSEcCtD
Fluoxymesterone—Seborrhoeic dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000563	0.0165	CcSEcCtD
Fluoxymesterone—Jaundice cholestatic—Mycophenolic acid—systemic scleroderma	0.000554	0.0162	CcSEcCtD
Fluoxymesterone—Gynaecomastia—Captopril—systemic scleroderma	0.000554	0.0162	CcSEcCtD
Fluoxymesterone—Jaundice cholestatic—Lisinopril—systemic scleroderma	0.000499	0.0146	CcSEcCtD
Fluoxymesterone—Coagulopathy—Mycophenolate mofetil—systemic scleroderma	0.000493	0.0145	CcSEcCtD
Fluoxymesterone—Menstruation irregular—Prednisone—systemic scleroderma	0.00047	0.0138	CcSEcCtD
Fluoxymesterone—Anaphylactoid reaction—Captopril—systemic scleroderma	0.000464	0.0136	CcSEcCtD
Fluoxymesterone—Hirsutism—Prednisone—systemic scleroderma	0.000448	0.0131	CcSEcCtD
Fluoxymesterone—Jaundice cholestatic—Mycophenolate mofetil—systemic scleroderma	0.000437	0.0128	CcSEcCtD
Fluoxymesterone—Amenorrhoea—Mycophenolate mofetil—systemic scleroderma	0.000437	0.0128	CcSEcCtD
Fluoxymesterone—Danazol—CCL2—systemic scleroderma	0.000415	1	CrCbGaD
Fluoxymesterone—Haemoglobin—Pentoxifylline—systemic scleroderma	0.000412	0.0121	CcSEcCtD
Fluoxymesterone—Haemorrhage—Pentoxifylline—systemic scleroderma	0.00041	0.012	CcSEcCtD
Fluoxymesterone—Anaphylactoid reaction—Leflunomide—systemic scleroderma	0.000383	0.0112	CcSEcCtD
Fluoxymesterone—ESR1—FOXM1 transcription factor network—CENPA—systemic scleroderma	0.000361	0.0256	CbGpPWpGaD
Fluoxymesterone—Gynaecomastia—Mycophenolate mofetil—systemic scleroderma	0.000344	0.0101	CcSEcCtD
Fluoxymesterone—Libido decreased—Lisinopril—systemic scleroderma	0.000343	0.0101	CcSEcCtD
Fluoxymesterone—PRLR—Cytokine Signaling in Immune system—IRF5—systemic scleroderma	0.000334	0.0237	CbGpPWpGaD
Fluoxymesterone—Anaphylactoid reaction—Lisinopril—systemic scleroderma	0.000329	0.00964	CcSEcCtD
Fluoxymesterone—PRLR—Cytokine Signaling in Immune system—IRF8—systemic scleroderma	0.000319	0.0226	CbGpPWpGaD
Fluoxymesterone—AR—Regulation of nuclear SMAD2/3 signaling—SMAD7—systemic scleroderma	0.000317	0.0225	CbGpPWpGaD
Fluoxymesterone—Disturbance in sexual arousal—Lisinopril—systemic scleroderma	0.000316	0.00926	CcSEcCtD
Fluoxymesterone—Anxiety—Pentoxifylline—systemic scleroderma	0.000303	0.00888	CcSEcCtD
Fluoxymesterone—Amenorrhoea—Prednisone—systemic scleroderma	0.000296	0.00869	CcSEcCtD
Fluoxymesterone—Anaphylactic shock—Pentoxifylline—systemic scleroderma	0.000291	0.00855	CcSEcCtD
Fluoxymesterone—Alopecia—Captopril—systemic scleroderma	0.000275	0.00806	CcSEcCtD
Fluoxymesterone—Haemoglobin—Azathioprine—systemic scleroderma	0.000273	0.008	CcSEcCtD
Fluoxymesterone—Haemorrhage—Azathioprine—systemic scleroderma	0.000271	0.00796	CcSEcCtD
Fluoxymesterone—Haemoglobin—Leflunomide—systemic scleroderma	0.000257	0.00755	CcSEcCtD
Fluoxymesterone—Haemorrhage—Leflunomide—systemic scleroderma	0.000256	0.00751	CcSEcCtD
Fluoxymesterone—Anaphylactic shock—Mometasone—systemic scleroderma	0.000251	0.00737	CcSEcCtD
Fluoxymesterone—Haemoglobin—Mycophenolic acid—systemic scleroderma	0.000246	0.0072	CcSEcCtD
Fluoxymesterone—Haemorrhage—Mycophenolic acid—systemic scleroderma	0.000244	0.00717	CcSEcCtD
Fluoxymesterone—ESR1—Regulation of nuclear SMAD2/3 signaling—SMAD7—systemic scleroderma	0.000244	0.0173	CbGpPWpGaD
Fluoxymesterone—NR3C1—Regulation of nuclear SMAD2/3 signaling—SMAD7—systemic scleroderma	0.000241	0.0171	CbGpPWpGaD
Fluoxymesterone—Alopecia—Azathioprine—systemic scleroderma	0.00024	0.00703	CcSEcCtD
Fluoxymesterone—AR—Regulation of nuclear SMAD2/3 signaling—COL1A2—systemic scleroderma	0.000231	0.0164	CbGpPWpGaD
Fluoxymesterone—AR—Androgen receptor signaling pathway—RHOB—systemic scleroderma	0.000227	0.0161	CbGpPWpGaD
Fluoxymesterone—Alopecia—Leflunomide—systemic scleroderma	0.000226	0.00664	CcSEcCtD
Fluoxymesterone—Paraesthesia—Mometasone—systemic scleroderma	0.000226	0.00662	CcSEcCtD
Fluoxymesterone—Anaphylactic shock—Captopril—systemic scleroderma	0.000221	0.00648	CcSEcCtD
Fluoxymesterone—Alopecia—Mycophenolic acid—systemic scleroderma	0.000216	0.00633	CcSEcCtD
Fluoxymesterone—Hypersensitivity—Pentoxifylline—systemic scleroderma	0.000215	0.0063	CcSEcCtD
Fluoxymesterone—ESR1—AP-1 transcription factor network—COL1A2—systemic scleroderma	0.0002	0.0142	CbGpPWpGaD
Fluoxymesterone—PRLR—Cytokine Signaling in Immune system—HLA-DQB1—systemic scleroderma	0.000199	0.0141	CbGpPWpGaD
Fluoxymesterone—Paraesthesia—Captopril—systemic scleroderma	0.000198	0.00582	CcSEcCtD
Fluoxymesterone—NR3C1—AP-1 transcription factor network—COL1A2—systemic scleroderma	0.000197	0.014	CbGpPWpGaD
Fluoxymesterone—Gynaecomastia—Methotrexate—systemic scleroderma	0.000195	0.00571	CcSEcCtD
Fluoxymesterone—Alopecia—Lisinopril—systemic scleroderma	0.000194	0.00571	CcSEcCtD
Fluoxymesterone—Haemoglobin—Mycophenolate mofetil—systemic scleroderma	0.000194	0.00569	CcSEcCtD
Fluoxymesterone—Haemorrhage—Mycophenolate mofetil—systemic scleroderma	0.000193	0.00566	CcSEcCtD
Fluoxymesterone—AR—Integrated Breast Cancer Pathway—SMAD7—systemic scleroderma	0.000193	0.0137	CbGpPWpGaD
Fluoxymesterone—PRLR—Cytokine Signaling in Immune system—IL1A—systemic scleroderma	0.000189	0.0134	CbGpPWpGaD
Fluoxymesterone—Anxiety—Leflunomide—systemic scleroderma	0.000189	0.00555	CcSEcCtD
Fluoxymesterone—Headache—Pentoxifylline—systemic scleroderma	0.000182	0.00535	CcSEcCtD
Fluoxymesterone—Anaphylactic shock—Leflunomide—systemic scleroderma	0.000182	0.00534	CcSEcCtD
Fluoxymesterone—Anxiety—Mycophenolic acid—systemic scleroderma	0.00018	0.00529	CcSEcCtD
Fluoxymesterone—AR—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000179	0.0127	CbGpPWpGaD
Fluoxymesterone—ESR1—Regulation of nuclear SMAD2/3 signaling—COL1A2—systemic scleroderma	0.000178	0.0126	CbGpPWpGaD
Fluoxymesterone—NR3C1—Regulation of nuclear SMAD2/3 signaling—COL1A2—systemic scleroderma	0.000176	0.0124	CbGpPWpGaD
Fluoxymesterone—Nausea—Pentoxifylline—systemic scleroderma	0.000173	0.00508	CcSEcCtD
Fluoxymesterone—Alopecia—Mycophenolate mofetil—systemic scleroderma	0.00017	0.005	CcSEcCtD
Fluoxymesterone—Paraesthesia—Leflunomide—systemic scleroderma	0.000163	0.00479	CcSEcCtD
Fluoxymesterone—Anaphylactoid reaction—Methotrexate—systemic scleroderma	0.000163	0.00479	CcSEcCtD
Fluoxymesterone—Anxiety—Lisinopril—systemic scleroderma	0.000163	0.00477	CcSEcCtD
Fluoxymesterone—Headache—Mometasone—systemic scleroderma	0.000157	0.00462	CcSEcCtD
Fluoxymesterone—Anaphylactic shock—Lisinopril—systemic scleroderma	0.000156	0.00459	CcSEcCtD
Fluoxymesterone—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.000156	0.00457	CcSEcCtD
Fluoxymesterone—Nausea—Mometasone—systemic scleroderma	0.000149	0.00438	CcSEcCtD
Fluoxymesterone—NR3C1—Glucocorticoid receptor regulatory network—IL13—systemic scleroderma	0.000149	0.0105	CbGpPWpGaD
Fluoxymesterone—ESR1—Integrated Breast Cancer Pathway—SMAD7—systemic scleroderma	0.000148	0.0105	CbGpPWpGaD
Fluoxymesterone—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000142	0.00418	CcSEcCtD
Fluoxymesterone—Hypersensitivity—Azathioprine—systemic scleroderma	0.000142	0.00416	CcSEcCtD
Fluoxymesterone—PRLR—Adipogenesis—TGFB1—systemic scleroderma	0.000142	0.0101	CbGpPWpGaD
Fluoxymesterone—Paraesthesia—Lisinopril—systemic scleroderma	0.00014	0.00412	CcSEcCtD
Fluoxymesterone—Headache—Captopril—systemic scleroderma	0.000138	0.00406	CcSEcCtD
Fluoxymesterone—ESR1—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000138	0.00978	CbGpPWpGaD
Fluoxymesterone—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000137	0.00402	CcSEcCtD
Fluoxymesterone—Hypersensitivity—Leflunomide—systemic scleroderma	0.000134	0.00393	CcSEcCtD
Fluoxymesterone—Haemoglobin—Prednisone—systemic scleroderma	0.000131	0.00385	CcSEcCtD
Fluoxymesterone—Nausea—Captopril—systemic scleroderma	0.000131	0.00385	CcSEcCtD
Fluoxymesterone—Haemorrhage—Prednisone—systemic scleroderma	0.000131	0.00383	CcSEcCtD
Fluoxymesterone—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000123	0.00361	CcSEcCtD
Fluoxymesterone—Headache—Azathioprine—systemic scleroderma	0.000121	0.00354	CcSEcCtD
Fluoxymesterone—AR—SIDS Susceptibility Pathways—IL13—systemic scleroderma	0.000117	0.0083	CbGpPWpGaD
Fluoxymesterone—Alopecia—Prednisone—systemic scleroderma	0.000115	0.00339	CcSEcCtD
Fluoxymesterone—Hypersensitivity—Lisinopril—systemic scleroderma	0.000115	0.00338	CcSEcCtD
Fluoxymesterone—Nausea—Azathioprine—systemic scleroderma	0.000114	0.00336	CcSEcCtD
Fluoxymesterone—Headache—Leflunomide—systemic scleroderma	0.000114	0.00334	CcSEcCtD
Fluoxymesterone—PRLR—Immune System—CSK—systemic scleroderma	0.000111	0.00787	CbGpPWpGaD
Fluoxymesterone—Haemoglobin—Methotrexate—systemic scleroderma	0.00011	0.00322	CcSEcCtD
Fluoxymesterone—Haemorrhage—Methotrexate—systemic scleroderma	0.000109	0.0032	CcSEcCtD
Fluoxymesterone—PRLR—Immune System—IRF5—systemic scleroderma	0.000109	0.00774	CbGpPWpGaD
Fluoxymesterone—Headache—Mycophenolic acid—systemic scleroderma	0.000109	0.00319	CcSEcCtD
Fluoxymesterone—ESR1—AP-1 transcription factor network—EDN1—systemic scleroderma	0.000108	0.00769	CbGpPWpGaD
Fluoxymesterone—ESR1—Plasma membrane estrogen receptor signaling—MMP2—systemic scleroderma	0.000108	0.00767	CbGpPWpGaD
Fluoxymesterone—Nausea—Leflunomide—systemic scleroderma	0.000108	0.00317	CcSEcCtD
Fluoxymesterone—NR3C1—AP-1 transcription factor network—EDN1—systemic scleroderma	0.000107	0.00757	CbGpPWpGaD
Fluoxymesterone—ESR1—FOXM1 transcription factor network—MMP2—systemic scleroderma	0.000106	0.00752	CbGpPWpGaD
Fluoxymesterone—PRLR—Immune System—IRF8—systemic scleroderma	0.000104	0.0074	CbGpPWpGaD
Fluoxymesterone—PRLR—Immune System—CD247—systemic scleroderma	0.000104	0.0074	CbGpPWpGaD
Fluoxymesterone—PRLR—Immune System—ITGAM—systemic scleroderma	0.000104	0.0074	CbGpPWpGaD
Fluoxymesterone—Nausea—Mycophenolic acid—systemic scleroderma	0.000103	0.00302	CcSEcCtD
Fluoxymesterone—PRLR—Signaling Pathways—SMAD7—systemic scleroderma	0.000102	0.00722	CbGpPWpGaD
Fluoxymesterone—ESR1—Plasma membrane estrogen receptor signaling—NOS3—systemic scleroderma	0.000101	0.00718	CbGpPWpGaD
Fluoxymesterone—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000101	0.00296	CcSEcCtD
Fluoxymesterone—PRLR—Cytokine Signaling in Immune system—IL1B—systemic scleroderma	9.88e-05	0.007	CbGpPWpGaD
Fluoxymesterone—Headache—Lisinopril—systemic scleroderma	9.79e-05	0.00287	CcSEcCtD
Fluoxymesterone—PRLR—Immune System—TNFAIP3—systemic scleroderma	9.77e-05	0.00693	CbGpPWpGaD
Fluoxymesterone—PRLR—Immune System—BLK—systemic scleroderma	9.66e-05	0.00684	CbGpPWpGaD
Fluoxymesterone—Anxiety—Prednisone—systemic scleroderma	9.65e-05	0.00283	CcSEcCtD
Fluoxymesterone—Alopecia—Methotrexate—systemic scleroderma	9.65e-05	0.00283	CcSEcCtD
Fluoxymesterone—Nausea—Lisinopril—systemic scleroderma	9.29e-05	0.00272	CcSEcCtD
Fluoxymesterone—Anaphylactic shock—Prednisone—systemic scleroderma	9.29e-05	0.00272	CcSEcCtD
Fluoxymesterone—ESR1—AP-1 transcription factor network—MMP1—systemic scleroderma	9.11e-05	0.00646	CbGpPWpGaD
Fluoxymesterone—NR3C1—AP-1 transcription factor network—MMP1—systemic scleroderma	8.98e-05	0.00636	CbGpPWpGaD
Fluoxymesterone—NR3C1—SIDS Susceptibility Pathways—IL13—systemic scleroderma	8.89e-05	0.0063	CbGpPWpGaD
Fluoxymesterone—Headache—Mycophenolate mofetil—systemic scleroderma	8.58e-05	0.00252	CcSEcCtD
Fluoxymesterone—Paraesthesia—Prednisone—systemic scleroderma	8.34e-05	0.00245	CcSEcCtD
Fluoxymesterone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—systemic scleroderma	8.23e-05	0.00583	CbGpPWpGaD
Fluoxymesterone—Nausea—Mycophenolate mofetil—systemic scleroderma	8.14e-05	0.00239	CcSEcCtD
Fluoxymesterone—ESR1—Plasma membrane estrogen receptor signaling—MMP9—systemic scleroderma	8.13e-05	0.00576	CbGpPWpGaD
Fluoxymesterone—ESR1—ATF-2 transcription factor network—MMP2—systemic scleroderma	8.09e-05	0.00573	CbGpPWpGaD
Fluoxymesterone—AR—Generic Transcription Pathway—SMAD7—systemic scleroderma	7.93e-05	0.00562	CbGpPWpGaD
Fluoxymesterone—PRLR—Immune System—CTLA4—systemic scleroderma	7.91e-05	0.00561	CbGpPWpGaD
Fluoxymesterone—NR3C1—Glucocorticoid receptor regulatory network—MMP1—systemic scleroderma	7.91e-05	0.00561	CbGpPWpGaD
Fluoxymesterone—PRLR—Signaling Pathways—RHOB—systemic scleroderma	7.88e-05	0.00559	CbGpPWpGaD
Fluoxymesterone—Anaphylactic shock—Methotrexate—systemic scleroderma	7.76e-05	0.00228	CcSEcCtD
Fluoxymesterone—PRLR—Signaling Pathways—HSPG2—systemic scleroderma	7.43e-05	0.00527	CbGpPWpGaD
Fluoxymesterone—ESR1—AP-1 transcription factor network—CCL2—systemic scleroderma	7.41e-05	0.00525	CbGpPWpGaD
Fluoxymesterone—AR—SIDS Susceptibility Pathways—IL1A—systemic scleroderma	7.37e-05	0.00523	CbGpPWpGaD
Fluoxymesterone—NR3C1—AP-1 transcription factor network—CCL2—systemic scleroderma	7.3e-05	0.00517	CbGpPWpGaD
Fluoxymesterone—PRLR—Signaling Pathways—CSK—systemic scleroderma	7.18e-05	0.00509	CbGpPWpGaD
Fluoxymesterone—Paraesthesia—Methotrexate—systemic scleroderma	6.97e-05	0.00204	CcSEcCtD
Fluoxymesterone—Hypersensitivity—Prednisone—systemic scleroderma	6.84e-05	0.00201	CcSEcCtD
Fluoxymesterone—PRLR—Immune System—HLA-DQB1—systemic scleroderma	6.51e-05	0.00462	CbGpPWpGaD
Fluoxymesterone—AR—Integrated Breast Cancer Pathway—MMP1—systemic scleroderma	6.4e-05	0.00453	CbGpPWpGaD
Fluoxymesterone—ESR1—Leptin signaling pathway—NOS3—systemic scleroderma	6.25e-05	0.00443	CbGpPWpGaD
Fluoxymesterone—PRLR—Immune System—IL1A—systemic scleroderma	6.19e-05	0.00438	CbGpPWpGaD
Fluoxymesterone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—systemic scleroderma	6.18e-05	0.00438	CbGpPWpGaD
Fluoxymesterone—PRLR—Immune System—CD40LG—systemic scleroderma	6.15e-05	0.00436	CbGpPWpGaD
Fluoxymesterone—ESR1—Generic Transcription Pathway—SMAD7—systemic scleroderma	6.11e-05	0.00433	CbGpPWpGaD
Fluoxymesterone—NR3C1—Generic Transcription Pathway—SMAD7—systemic scleroderma	6.02e-05	0.00427	CbGpPWpGaD
Fluoxymesterone—Headache—Prednisone—systemic scleroderma	5.82e-05	0.00171	CcSEcCtD
Fluoxymesterone—Hypersensitivity—Methotrexate—systemic scleroderma	5.72e-05	0.00168	CcSEcCtD
Fluoxymesterone—NR3C1—SIDS Susceptibility Pathways—IL1A—systemic scleroderma	5.59e-05	0.00396	CbGpPWpGaD
Fluoxymesterone—Nausea—Prednisone—systemic scleroderma	5.52e-05	0.00162	CcSEcCtD
Fluoxymesterone—ESR1—Leptin signaling pathway—IL1B—systemic scleroderma	5.32e-05	0.00377	CbGpPWpGaD
Fluoxymesterone—ESR1—AP-1 transcription factor network—MMP9—systemic scleroderma	5.3e-05	0.00376	CbGpPWpGaD
Fluoxymesterone—NR3C1—AP-1 transcription factor network—MMP9—systemic scleroderma	5.22e-05	0.0037	CbGpPWpGaD
Fluoxymesterone—ESR1—Integrated Breast Cancer Pathway—MMP1—systemic scleroderma	4.93e-05	0.00349	CbGpPWpGaD
Fluoxymesterone—Headache—Methotrexate—systemic scleroderma	4.86e-05	0.00143	CcSEcCtD
Fluoxymesterone—Nausea—Methotrexate—systemic scleroderma	4.61e-05	0.00135	CcSEcCtD
Fluoxymesterone—ESR1—Regulation of Telomerase—TGFB1—systemic scleroderma	4.47e-05	0.00317	CbGpPWpGaD
Fluoxymesterone—NR3C1—Endoderm Differentiation—TGFB1—systemic scleroderma	4.4e-05	0.00312	CbGpPWpGaD
Fluoxymesterone—AR—Generic Transcription Pathway—CTGF—systemic scleroderma	4.38e-05	0.00311	CbGpPWpGaD
Fluoxymesterone—ESR1—AP-1 transcription factor network—TGFB1—systemic scleroderma	4.37e-05	0.0031	CbGpPWpGaD
Fluoxymesterone—NR3C1—AP-1 transcription factor network—TGFB1—systemic scleroderma	4.3e-05	0.00305	CbGpPWpGaD
Fluoxymesterone—PRLR—Signaling Pathways—EDN1—systemic scleroderma	4.02e-05	0.00285	CbGpPWpGaD
Fluoxymesterone—AR—SIDS Susceptibility Pathways—IL1B—systemic scleroderma	3.84e-05	0.00272	CbGpPWpGaD
Fluoxymesterone—AR—Gene Expression—SMAD7—systemic scleroderma	3.82e-05	0.00271	CbGpPWpGaD
Fluoxymesterone—AR—Gene Expression—TNFSF13—systemic scleroderma	3.55e-05	0.00252	CbGpPWpGaD
Fluoxymesterone—ESR1—Generic Transcription Pathway—CTGF—systemic scleroderma	3.38e-05	0.00239	CbGpPWpGaD
Fluoxymesterone—NR3C1—Generic Transcription Pathway—CTGF—systemic scleroderma	3.33e-05	0.00236	CbGpPWpGaD
Fluoxymesterone—PRLR—Immune System—IL1B—systemic scleroderma	3.23e-05	0.00229	CbGpPWpGaD
Fluoxymesterone—ESR1—Gene Expression—SMAD7—systemic scleroderma	2.94e-05	0.00209	CbGpPWpGaD
Fluoxymesterone—NR3C1—SIDS Susceptibility Pathways—IL1B—systemic scleroderma	2.92e-05	0.00207	CbGpPWpGaD
Fluoxymesterone—NR3C1—Gene Expression—SMAD7—systemic scleroderma	2.9e-05	0.00205	CbGpPWpGaD
Fluoxymesterone—PRLR—Signaling Pathways—CCL2—systemic scleroderma	2.75e-05	0.00195	CbGpPWpGaD
Fluoxymesterone—ESR1—Gene Expression—TNFSF13—systemic scleroderma	2.73e-05	0.00194	CbGpPWpGaD
Fluoxymesterone—NR3C1—Gene Expression—TNFSF13—systemic scleroderma	2.69e-05	0.00191	CbGpPWpGaD
Fluoxymesterone—NR3C1—Adipogenesis—TGFB1—systemic scleroderma	2.62e-05	0.00186	CbGpPWpGaD
Fluoxymesterone—AR—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	2.54e-05	0.0018	CbGpPWpGaD
Fluoxymesterone—PRLR—Signaling Pathways—NOS3—systemic scleroderma	2.45e-05	0.00174	CbGpPWpGaD
Fluoxymesterone—AR—Gene Expression—CTGF—systemic scleroderma	2.11e-05	0.0015	CbGpPWpGaD
Fluoxymesterone—PRLR—Signaling Pathways—MMP9—systemic scleroderma	1.97e-05	0.00139	CbGpPWpGaD
Fluoxymesterone—ESR1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	1.96e-05	0.00139	CbGpPWpGaD
Fluoxymesterone—ESR1—Signaling Pathways—SMAD7—systemic scleroderma	1.91e-05	0.00136	CbGpPWpGaD
Fluoxymesterone—ESR1—Gene Expression—CTGF—systemic scleroderma	1.63e-05	0.00115	CbGpPWpGaD
Fluoxymesterone—PRLR—Signaling Pathways—TGFB1—systemic scleroderma	1.62e-05	0.00115	CbGpPWpGaD
Fluoxymesterone—NR3C1—Gene Expression—CTGF—systemic scleroderma	1.6e-05	0.00114	CbGpPWpGaD
Fluoxymesterone—ESR1—Signaling Pathways—RHOB—systemic scleroderma	1.48e-05	0.00105	CbGpPWpGaD
Fluoxymesterone—ESR1—Signaling Pathways—HSPG2—systemic scleroderma	1.4e-05	0.000989	CbGpPWpGaD
Fluoxymesterone—ESR1—Signaling Pathways—CSK—systemic scleroderma	1.35e-05	0.000955	CbGpPWpGaD
Fluoxymesterone—ESR1—Signaling Pathways—EDN1—systemic scleroderma	7.55e-06	0.000535	CbGpPWpGaD
Fluoxymesterone—ESR1—Signaling Pathways—CCL2—systemic scleroderma	5.16e-06	0.000366	CbGpPWpGaD
Fluoxymesterone—ESR1—Signaling Pathways—NOS3—systemic scleroderma	4.6e-06	0.000326	CbGpPWpGaD
Fluoxymesterone—ESR1—Signaling Pathways—MMP9—systemic scleroderma	3.69e-06	0.000262	CbGpPWpGaD
Fluoxymesterone—ESR1—Signaling Pathways—TGFB1—systemic scleroderma	3.04e-06	0.000216	CbGpPWpGaD
